Analysts Set Expectations for Biomea Fusion Q3 Earnings

Key Points

• Brookline Capital Markets expects Biomea Fusion to report a Q3 2026 loss of $0.18 per share and maintains a “Buy” rating. Its full-year 2026 loss estimate is $0.65 per share.
• Biomea previously reported a Q2 loss of $0.12 per share, beating analyst expectations for a $0.22 loss by $0.10. The stock has a “Moderate Buy” consensus rating from analysts, with a $9.00 target price.
• Shares opened at $1.37, while institutional investors own 96.72% of the company; Renaissance Technologies increased its position by 174.3% during the first quarter.

Biomea Fusion, Inc. (NASDAQ:BMEA - Free Report) - Investment analysts at Brookline Capital Markets issued their Q3 2026 EPS estimates for Biomea Fusion in a research report issued to clients and investors on Wednesday, October 7th. Brookline Capital Markets analyst K. Raja anticipates that the company will earn ($0.18) per share for the quarter. Brookline Capital Markets has a "Buy" rating on the stock. The consensus estimate for Biomea Fusion's current full-year earnings is ($0.73) per share. Brookline Capital Markets also issued estimates for Biomea Fusion's Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.65) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.77) EPS, FY2029 earnings at ($0.80) EPS and FY2030 earnings at ($0.84) EPS.

Biomea Fusion (NASDAQ:BMEA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.10.

Several other analysts have also issued reports on BMEA. Citigroup reiterated a "market outperform" rating on shares of Biomea Fusion in a research report on Wednesday, September 30th. Wall Street Zen upgraded shares of Biomea Fusion from a "sell" rating to a "hold" rating in a research report on Monday. Weiss Ratings restated a "sell (e+)" rating on shares of Biomea Fusion in a research report on Monday, September 28th. Finally, HC Wainwright restated a "buy" rating on shares of Biomea Fusion in a research note on Monday, August 24th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $9.00.

Biomea Fusion Trading Up 3.8%

NASDAQ BMEA opened at $1.37 on Friday. The company has a market cap of $99.30 million, a price-to-earnings ratio of -4.72 and a beta of -0.28. The company has a 50 day moving average of $1.52 and a 200-day moving average of $1.46. Biomea Fusion has a 1-year low of $0.87 and a 1-year high of $2.24.

Institutional Investors Weigh In On Biomea Fusion

A number of institutional investors have recently made changes to their positions in the stock. Rathbones Group PLC bought a new stake in shares of Biomea Fusion in the first quarter valued at approximately $57,000. ADAR1 Capital Management LLC purchased a new position in Biomea Fusion in the 2nd quarter valued at approximately $64,000. GSA Capital Partners LLP bought a new stake in Biomea Fusion during the 2nd quarter valued at $318,000. BlackRock Inc. bought a new stake in Biomea Fusion during the 2nd quarter valued at $1,052,000. Finally, Renaissance Technologies LLC lifted its position in shares of Biomea Fusion by 174.3% during the first quarter. Renaissance Technologies LLC now owns 1,312,798 shares of the company's stock worth $2,009,000 after acquiring an additional 834,179 shares in the last quarter. Institutional investors own 96.72% of the company's stock.

About Biomea Fusion

Biomea Fusion, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for serious diseases with significant unmet medical needs. The company's research platform is centered on covalent chemistry, an approach designed to create potentially durable interactions between medicines and their biological targets.

Biomea's lead investigational product is icovamenib, formerly known as BMF-219, an oral covalent menin inhibitor. The company has evaluated icovamenib in oncology indications, including certain blood cancers, and is also investigating its potential in metabolic diseases such as diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.